Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men

American Journal of Hypertension

Volumn 27, Issue 4, 2014, Pages 620-627

  Asferg, Camilla L ^a   Nielsen, Søren J ^b   Andersen, Ulrik B ^a   Linneberg, Allan ^a,c   Møller, Daniel V ^d   Hedley, Paula L ^d   Christiansen, Michael ^d   Gøtze, Jens P ^c,e   Jeppesen, Jørgen L ^a,c  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

Blood pressure; Body composition; Glucose; Hypertension; Insulin; Natriuretic peptides; Obesity

Indexed keywords

GLUCOSE; INSULIN; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR; GLUCOSE BLOOD LEVEL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; AGED; BLOOD; BODY MASS; CROSS-SECTIONAL STUDY; METABOLISM;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY;

EID: 84897866362     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt145     Document Type: Article

References (33)

1. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011; 301:H12-H20.
2. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26:831-843.
3. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009; 41:348-353.
4. Jeppesen J, Nielsen SJ, Torp-Pedersen C, Hansen TW, Olsen MH, Berg ND, Linneberg A, Madsbad S, Fenger M. Genetic variation in the natriuretic peptide system, circulating natriuretic peptide levels, and blood pressure: an ambulatory blood pressure study. Am J Hypertens 2012; 25:1095-1100.
5. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600.
6. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jorgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46:660-666.
7. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112:2163-2168.
8. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007; 115: 1345-1353.
9. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS, Vasan RS, Melander O, Wang TJ. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 2011; 96:3242-3249.
10. Fox ER, Musani SK, Bidulescu A, Nagarajarao HS, Samdarshi TE, Gebreab SY, Sung JH, Steffes MW, Wang TJ, Taylor HA, Vasan RS. Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. Circulation 2011; 124:1021-1027.
11. Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, Khan AM, Levy D, Hoffmann U, O'Donnell CJ, Miller KK, Newton-Cheh C, Coviello AD, Bhasin S, Vasan RS, Wang TJ. Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 2011; 108:979-984.
12. Nakatsuji H, Kishida K, Funahashi T, Nakagawa T, Shimomura I. Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution. Cardiovasc Diabetol 2012; 11:22.
13. Mizuno Y, Harada E, Katoh D, Kashiwagi Y, Morikawa Y, Nakagawa H, Yoshimura M, Saito Y, Yasue H. Cardiac production of B-type natriuretic peptide is inversely related to the plasma level of free fatty acids in obese individuals-possible involvement of the insulin resistance. Endocr J 2013; 60:87-95.
14. Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, Nikiforova VJ, Bergmann A, Kruse M, Seltmann AC, Bluher M, Pfeiffer AF, Rudovich N. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab 2012; 97:E731-E739.
15. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Moller DV, Hedley PL, Christiansen M, Goetze JP, Esler M, Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension 2013; 62:147-153.
16. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 1986; 38:1827-1833.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
18. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-545.
20. Hansen TW, Kikuya M, Thijs L, Li Y, Boggia J, Bjorklund-Bodegard K, Torp-Pedersen C, Jeppesen J, Ibsen H, Staessen JA. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis- clinical implications. J Clin Hypertens 2008; 10:377-381.
21. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, Willett D, Victor RG. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005; 46:124-129.
22. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011; 278:1808-1817.
23. Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Fail Rev 2012; 17:81-96.
24. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006; 152:1071-1076.
25. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994; 23:I20-I24.
26. Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. Endocrinology 2010; 151:5218-5225.
27. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, Giantomassi L, Rappelli A. Plasma atrial natriurectic peptide and natriurectic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997; 15:1695-1699.
28. Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, Nikiforova VJ, Bergmann A, Kruse M, Seltmann AC, Bluher M, Pfeiffer AF, Rudovich N. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab 2012; 97:E731-E739.
29. Date T, Yamane T, Yamashita S, Matsuo S, Matsushima M, Inada K, Taniguchi I, Yoshimura M. Paradoxical clearance of natriuretic peptide between pulmonary and systemic circulation: a pulmonary mechanism of maintaining natriuretic peptide plasma concentration in obese individuals. J Clin Endocrinol Metab 2012; 97:E14-E21.
30. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000; 14:1345-1351.
31. Sengenes C, Stich V, Berlan M, Hejnova J, Lafontan M, Pariskova Z, Galitzky J. Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int J Obes Relat Metab Disord 2002; 26:24-32.
32. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012; 122:1022-1036.
33. Engeli S, Birkenfeld AL, Badin PM, Bourlier V, Louche K, Viguerie N, Thalamas C, Montastier E, Larrouy D, Harant I, de Glisezinski I, Lieske S, Reinke J, Beckmann B, Langin D, Jordan J, Moro C. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012; 122:4675-4679.